Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Current Leases: 2020-2024

Historic Current Leases for Gyre Therapeutics (GYRE) over the last 5 years, with Dec 2024 value amounting to $713,000.

  • Gyre Therapeutics' Current Leases fell 9.80% to $626,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $626,000, marking a year-over-year decrease of 9.80%. This contributed to the annual value of $713,000 for FY2024, which is 239.52% up from last year.
  • According to the latest figures from FY2024, Gyre Therapeutics' Current Leases is $713,000, which was up 239.52% from $210,000 recorded in FY2023.
  • In the past 5 years, Gyre Therapeutics' Current Leases ranged from a high of $2.0 million in FY2021 and a low of $210,000 during FY2023.
  • Over the past 3 years, Gyre Therapeutics' median Current Leases value was $492,000 (recorded in 2022), while the average stood at $471,667.
  • In the last 5 years, Gyre Therapeutics' Current Leases tumbled by 75.11% in 2022 and then skyrocketed by 239.52% in 2024.
  • Gyre Therapeutics' Current Leases (Yearly) stood at $663,000 in 2020, then surged by 198.19% to $2.0 million in 2021, then crashed by 75.11% to $492,000 in 2022, then plummeted by 57.32% to $210,000 in 2023, then spiked by 239.52% to $713,000 in 2024.